Clinical Trial Update: Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating PVX-410 in combination with pembrolizumab and chemotherapy for metastatic PD-L1 positive triple-negative breast cancer is ongoing with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• PVX-410
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: OncoPep, Inc. | Conditions: Metastatic Triple-Negative Breast Carcinoma | Phase 2 | Status: UNKNOWN